GlassScriptPhysician profile
Albert J Martins
NPI 1346203106
$6,854.94
in general payments reported to CMS, 2019-2025
35 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $522 · 2021: $1,066 · 2022: $1,308 · 2023: $1,010 · 2024: $1,209 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,607.20 | 2019-2025 | |
| Lilly USA, LLC | $562.90 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Abbvie INC. | $557.90 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $465.02 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $446.10 | 2019-2024 | Vumerity |
| Ucb, INC. | $356.32 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Lundbeck LLC | $344.68 | 2021-2025 | Vyepti |
| Pfizer INC. | $340.74 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $306.06 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $177.48 | 2019-2025 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $165.57 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $139.43 | 2019-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $134.88 | 2022-2023 | Amvuttra, Onpattro |
| Eisai INC. | $131.44 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $113.51 | 2025 | Valtoco |
| Argenx US, INC. | $92.77 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $91.67 | 2025 | Symbravo |
| Genzyme Corporation | $75.18 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $74.58 | 2020-2021 | |
| Genentech USA, INC. | $71.34 | 2022-2025 | Ocrevus Zunovo |
| Impel Pharmaceuticals INC. | $62.83 | 2022-2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $61.11 | 2021-2022 | |
| Allergan, INC. | $59.01 | 2020 | |
| Celgene Corporation | $48.83 | 2025 | Zeposia |
| Biotronik Nro, INC. | $40.62 | 2024-2025 | Prospera |
| Vertical Pharmaceuticals, LLC | $24.67 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $22.97 | 2022 | |
| Acadia Pharmaceuticals INC | $22.38 | 2019 | |
| Abbott Laboratories | $20.69 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $20.03 | 2024 | |
| Vanda Pharmaceuticals INC. | $19.31 | 2022 | |
| Philips North America LLC | $17.60 | 2022 | |
| Currax Pharmaceuticals LLC | $15.64 | 2025 | Onzetra Xsail |
| Livanova USA, INC. | $15.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Martins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.